Behind the Mystery: Acute Hepatic Porphyria (AHP)
April 12, 2021
Acute hepatic porphyria, or AHP, refers to a family of rare, genetic diseases characterized by potentially life-threatening attacks and, for some people, chronic pain and other debilitating symptoms that negatively impact everyday life.
Severe, unexplained abdominal pain is the most common symptom of AHP, and people may also experience nausea, vomiting, seizures, anxiety and depression, and pain in their limbs, back, or chest. Because AHP is so rare and its symptoms resemble those of more common conditions, misdiagnosis is common, which can lead to unnecessary treatments, surgeries, and hospital stays. In fact, people with AHP can wait up to 15 years for an accurate and confirmed diagnosis. Common misdiagnoses include depression, endometriosis, and fibromyalgia, as well as gastrointestinal disorders like irritable bowel syndrome and appendicitis.
One of the most definitive techniques a doctor uses to help determine if a patient has AHP is a urine test, which includes analysis of PBG (porphobilinogen), ALA (aminolevulinic acid), and porphyrin levels. We met with Dr. Angelika Erwin, a porphyria expert and member of the Porphyrias Consortium, as well as Nicole, who shares her experience living with AHP and recounts her 12-year search for a diagnosis.
To learn more about AHP, speak with your doctor. You can also visit Alnylam’s www.PinpointAHP.com for educational information and resources.
Sponsored by Alnylam Pharmaceuticals, Inc. AS1-USA-00913
Bringing the best tips from the experts in Atlanta in business, beauty, wealth management, child healthcare, car shopping, and more. Each year, Atlanta’s Women’s Entrepreneurship Initiative selects 15 local female entrepreneurs for a 15-month business training program. We meet women who have grown their companies, created jobs, and broke through the glass ceiling. With some […]
iMCD is the deadliest subtype of Castleman disease. Approximately one third of patients die within five years of diagnosis, and another third die within 10 years if not treated.
There are no effective treatment options for people with unresectable or metastatic chondrosarcoma despite many attempts by multiple pharmaceutical companies over the past few decades.